Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.

Phillippi K, Hoeltzel M, Byun Robinson A, Kim S; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry Investigators.

J Pediatr. 2017 May;184:38-44.e1. doi: 10.1016/j.jpeds.2017.01.046. Epub 2017 Mar 3.

PMID:
28410093
2.

Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.

Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL; Childhood Myositis Heterogeneity Study Group.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):1088-1094. doi: 10.1002/acr.23113.

PMID:
28129483
3.

HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis.

Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas JP, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Mellins ED, Ilowite NT, Russo R, Len C, Hilario MO, Oliveira S, Yeung RS, Rosenberg A, Wedderburn LR, Anton J, Schwarz T, Hinks A, Bilginer Y, Park J, Cobb J, Satorius CL, Han B, Baskin E, Signa S, Duerr RH, Achkar JP, Kamboh MI, Kaufman KM, Kottyan LC, Pinto D, Scherer SW, Alarcón-Riquelme ME, Docampo E, Estivill X, Gül A; British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group; Childhood Arthritis Prospective Study (CAPS) Group; Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators; Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group; Biologically Based Outcome Predictors in JIA (BBOP) Group, de Bakker PI, Raychaudhuri S, Langefeld CD, Thompson S, Zeggini E, Thomson W, Kastner DL, Woo P; International Childhood Arthritis Genetics (INCHARGE) Consortium.

Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15970-5. doi: 10.1073/pnas.1520779112. Epub 2015 Nov 23.

4.

Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.

Habers GE, Huber AM, Mamyrova G, Targoff IN, O'Hanlon TP, Adams S, Pandey JP, Boonacker C, van Brussel M, Miller FW, van Royen-Kerkhof A, Rider LG; Childhood Myositis Heterogeneity Study Group.

Arthritis Rheumatol. 2016 Mar;68(3):761-8. doi: 10.1002/art.39466.

5.

Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis.

Autmizguine J, Cohen-Wolkowiez M, Ilowite N; RAPPORT Investigators.

J Clin Pharmacol. 2015 Jan;55(1):39-44. doi: 10.1002/jcph.372. Epub 2014 Aug 22. No abstract available.

6.

Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.

Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, Verbsky JW, Spalding SJ, Kimura Y, Imundo LF, Punaro MG, Sherry DD, Tarvin SE, Zemel LS, Birmingham JD, Gottlieb BS, Miller ML, O'Neil K, Ruth NM, Wallace CA, Singer NG, Sandborg CI.

Arthritis Rheumatol. 2014 Sep;66(9):2570-9. doi: 10.1002/art.38699.

7.

Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies.

Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.

Arthritis Care Res (Hoboken). 2014 May;66(5):732-40. doi: 10.1002/acr.22212.

8.

Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders.

Miller FW, Cooper RG, Vencovský J, Rider LG, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake TR, Isenberg DA, Chinoy H, Ollier WE, O'Hanlon TP, Peng B, Lee A, Lamb JA, Chen W, Amos CI, Gregersen PK; Myositis Genetics Consortium.

Arthritis Rheum. 2013 Dec;65(12):3239-47. doi: 10.1002/art.38137.

9.

The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.

Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW; Childhood Myositis Heterogeneity Collaborative Study Group.

Medicine (Baltimore). 2013 Jul;92(4):223-43. doi: 10.1097/MD.0b013e31829d08f9.

10.

Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis.

Shah M, Targoff IN, Rice MM, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.

Arthritis Rheum. 2013 Jul;65(7):1934-41. doi: 10.1002/art.37985.

11.

Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies.

Henderson LA, Loring SH, Gill RR, Liao KP, Ishizawar R, Kim S, Perlmutter-Goldenson R, Rothman D, Son MB, Stoll ML, Zemel LS, Sandborg C, Dellaripa PF, Nigrovic PA.

J Rheumatol. 2013 Mar;40(3):273-81. doi: 10.3899/jrheum.121048. Epub 2013 Feb 1.

12.

The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.

Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.

Medicine (Baltimore). 2013 Jan;92(1):25-41. doi: 10.1097/MD.0b013e31827f264d.

13.

Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies.

Rider LG, Wu L, Mamyrova G, Targoff IN, Miller FW; Childhood Myositis Heterogeneity Collaborative Study Group.

Rheumatology (Oxford). 2010 Dec;49(12):2381-90. doi: 10.1093/rheumatology/keq277. Epub 2010 Aug 27.

14.

Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.

Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, Villalba ML, Myones BL, Pachman LM, Rennebohm RM, Reed AM, Miller FW; IMACS Group.

Arthritis Rheum. 2009 Nov;60(11):3425-35. doi: 10.1002/art.24904.

15.

Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis.

Mamyrova G, O'Hanlon TP, Sillers L, Malley K, James-Newton L, Parks CG, Cooper GS, Pandey JP, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.

Arthritis Rheum. 2008 Dec;58(12):3941-50. doi: 10.1002/art.24039.

16.

A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis.

Foeldvari I, Szer IS, Zemel LS, Lovell DJ, Giannini EH, Robbins JL, West CR, Steidle G, Krishnaswami S, Bloom BJ.

J Rheumatol. 2009 Jan;36(1):174-82. doi: 10.3899/jrheum.080073.

PMID:
19012356
17.

Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity.

Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG; Childhood Myositis Heterogeneity Study Group.

Medicine (Baltimore). 2008 Mar;87(2):70-86. doi: 10.1097/MD.0b013e31816bc604.

18.

Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats.

Huber AM, Lachenbruch PA, Dugan EM, Miller FW, Rider LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Arthritis Rheum. 2008 Mar 15;59(3):352-6. doi: 10.1002/art.23313.

19.

Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis.

Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, Rider LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Arthritis Rheum. 2008 Feb 15;59(2):214-21. doi: 10.1002/art.23340.

20.

The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy.

Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, Rider LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Rheumatology (Oxford). 2007 Oct;46(10):1606-11.

Supplemental Content

Loading ...
Support Center